PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer

Publication: ESMO 2026 Authors: L. Van't Veer; Laboratory Medicine, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, United States of America Title: AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer Abstract Background: MammaPrint (MP) is Read More

70-Gene Signature Provides Prognostic Value Beyond Ki67 in HR+HER2– Early Breast Cancer (EBC)

Publication: ESMO 2026 Authors: Michael Gnant, Mehran Habibi, Adam Brufsky, Laila Samiian, Sasha Davis, Eduardo Dias, Virginia Borges, Kent Hoskins, VK Gadi, Cynthia Osborne, Rakhshanda Layeequr-Rahman, Alfredo Santillan, Harshini Ramaswamy, Raquel Weber, Andrea Menicucci, William Audeh and Joyce O’Shaughnessy. Title: 70-Gene Signature Provides Prognostic Value Beyond Ki67 in HR+HER2– Read More

Impact of Germline BRCA1 and BRCA2 Mutations on 70-Gene Signature Risk for patients enrolled in the FLEX Study

Publication: ESMO 2026 Authors: Amir Sonnenblick (first and presenting), Mehran Habibi, Laura Lee, Eduardo Dias, Alfredo Santillan, Beth Sieling, Nicole Sookhan, Laila Samiian, Sasha Strain, Jaime Alberty, Massimo Cristofanelli, Priscilla McAuliffe, Samuel Benjamin, Sahra Uygun, Nicole Stivers, Raquel Weber, Andrea Menicucci, Willan Audeh, Joyce O'Shaughnessy Title: Impact of Germline Read More

Prediction of Anthracycline Benefit in Hormone Receptor– Positive, Human Epidermal Growth Factor Receptor 2– Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study

Publication: JCO Precis Oncol, June 2026 DOI https://doi.org/10.1200/PO-25-01285 Authors: Joyce O'Shaughnessy et al. Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstract Purpose: Randomized trials have not demonstrated clear benefit from anthracyclines for patients with hormone receptor–positive, human epidermal growth Read More

Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy

Publication: ASCO 2026, Abstract #621 Authors: David Page Title: Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer Abstract Background: Neoadjuvant outcomes are variable in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), highlighting the unmet need for predictive biomarkers. Read More

Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers

Publication: ASCO 2026, Abstract #561 Authors: Steve Isakoff Title: Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers Abstract Background: Homologous recombination deficiency (HRD) is a biomarker for impaired DNA repair proficiency and genomic instability, associated with sensitivity to DNA-damaging agents. Read More